spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Methylnaltrexone 

 HSMN NewsFeed - 26 Jun 2018
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA(TM) (lofexidine)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Dec 2017
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Dec 2016
Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2014
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jan 2013
FDA Approves Fulyzaq(TM) (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART)
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Aug 2009
New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Biopharmaceuticals
 HSMN NewsFeed - 7 Jul 2008
A.P. Pharma Appoints Ronald J. Prentki as President, Chief Executive Officer and Member of Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jul 2008
European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jul 2008
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2008
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Mar 2008
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2007
Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2007
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 May 2007
Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 May 2007
Wyeth and Progenics Pharmaceuticals Announce Submission of Marketing Application in Europe for the Subcutaneous Formulation of Methylnaltrexone
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 30 Mar 2007
Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2006
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2006
Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
Methylnaltrexone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.